MarketCapExport financials
Arbutus Biopharma Corporation (ABUS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Arbutus Biopharma Corporation Balance Sheet 2025-2010 | ABUS
Brief overview of Arbutus Biopharma Corporation's balance sheet structure
This overview follows the five latest available annual observations between 2021 and 2025.
Assets fell from $204.5 million to $94.6 million. This may reflect either deliberate optimization or a reduction in business scale.
Asset growth of -53.7% was close to the -48.5% change in liabilities, leaving the funding profile broadly stable.
The equity-to-assets ratio is 80.9%, compared with 82.9% five periods ago. The balance sheet has a substantial internal cushion.
Cash equals 19% of the balance sheet, compared with 53.4% five periods ago. This is the readily available cushion.
The balance sheet includes a negative accumulated result of -$1.4 billion. It should be assessed alongside historical profits and capital distributions.
Conclusion
Arbutus Biopharma Corporation's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet Arbutus Biopharma Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -35 M | - | -28.6 M | -107 M | -49.3 M | -28.4 M | -36.9 M | -42.3 M | -11.4 M | -167 M | -72.2 M | -68.7 M | -47 M | -9 M | - |
Long Term Debt |
- | 806 K | - | 1.82 M | 2.23 M | 2.59 M | - | - | 12 M | 12 M | - | - | - | - | - | - |
Long Term Debt Current |
547 K | 483 K | 425 K | 372 K | 383 K | 390 K | 340 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 25.6 M | 25 M | 16.4 M | 40.1 M | 62.3 M | 154 M | 9.94 M | - | 723 K | 1.66 M | - |
Total Current Liabilities |
6.01 M | 15.6 M | 22.5 M | 32.9 M | 11.2 M | 9.54 M | 7.83 M | 11.2 M | 14.6 M | 10.6 M | 10.6 M | 20.2 M | - | - | - | - |
Total Liabilities |
18 M | 34.3 M | 38.4 M | 58.6 M | 35 M | 35.1 M | 32.8 M | 27.7 M | 54.7 M | 72.9 M | 165 M | 30.1 M | 12.5 M | 11.7 M | 8.5 M | - |
Deferred Revenue |
- | 7.57 M | 11.8 M | 16.5 M | - | - | - | - | 2.74 M | 15 K | 868 K | 5.78 M | 3.46 M | 3.14 M | 2.75 M | - |
Retained Earnings |
-1.38 B | -1.35 B | -1.28 B | -1.2 B | -1.13 B | -1.05 B | -970 M | -805 M | -738 M | -651 M | -267 M | -206 M | -167 M | -230 M | -254 M | - |
Total Assets |
94.6 M | 132 M | 144 M | 195 M | 204 M | 137 M | 106 M | 228 M | 237 M | 276 M | 712 M | 118 M | 71.7 M | 52.6 M | 13.7 M | - |
Cash and Cash Equivalents |
18 M | 36.3 M | 26.3 M | 30.8 M | 109 M | 52.3 M | 31.8 M | 36.9 M | 54.3 M | 23.4 M | 167 M | 72.2 M | 68.7 M | 47 M | 9.03 M | 12.4 M |
Book Value |
76.6 M | 97.4 M | 106 M | 137 M | 169 M | 102 M | 72.7 M | 200 M | 182 M | 203 M | 548 M | 88 M | 59.2 M | 40.9 M | 5.21 M | - |
Total Shareholders Equity |
76.6 M | 97.4 M | 106 M | 137 M | 169 M | 102 M | 72.7 M | 200 M | 182 M | 203 M | 548 M | 88 M | 59.2 M | 40.9 M | 5.23 M | 10.8 M |
All numbers in USD currency
Quarterly Balance Sheet Arbutus Biopharma Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
199 K | - | 806 K | - | - | - | 806 K | - | - | - | 1.34 M | - | - | - | 1.82 M | - | - | - | 2.23 M | 2.36 M | 2.48 M | 2.48 M | 2.59 M | 2.59 M | 2.59 M | 2.59 M | 3.02 M | 3.02 M | 3.02 M | 3.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
18 M | 17 M | 34.3 M | 20.3 M | 20.3 M | 37.9 M | 34.3 M | 33.6 M | 37.6 M | 35.7 M | 38.4 M | 39.3 M | 42.1 M | 47.3 M | 58.6 M | 58.3 M | - | 71 M | 35 M | 35.5 M | 34.5 M | 32.1 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 54.7 M | 54.7 M | 54.7 M | 54.7 M | 72.9 M | 72.9 M | 72.9 M | 72.9 M | 165 M | 165 M | 165 M | 165 M | 30.1 M | 30.1 M | 30.1 M | 30.1 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | 7.57 M | - | - | 6.76 M | 7.57 M | 10.9 M | 11 M | 11.5 M | 11.8 M | 12.1 M | 15.3 M | 15.1 M | 16.5 M | 14.9 M | - | 23.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | 649 K | 974 K | 1.72 M | 2.74 M | 15 K | 2.62 M | 2.62 M | 15 K | 15 K | 15 K | 15 K | 868 K | 868 K | 868 K | 868 K | 5.78 M | 5.78 M | 5.78 M | 5.78 M | 3.46 M | 3.46 M | 3.46 M | 3.46 M | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.38 B | -1.21 B | -1.35 B | -1.38 B | -1.37 B | -1.37 B | -1.35 B | -1.33 B | -1.31 B | -1.29 B | -1.28 B | -1.26 B | -1.24 B | -1.22 B | -1.2 B | -1.18 B | - | -1.15 B | -1.13 B | -1.11 B | -1.09 B | -1.07 B | -1.05 B | -1.05 B | -1.05 B | -1.05 B | -970 M | -970 M | -970 M | -970 M | -805 M | -805 M | -805 M | -805 M | -738 M | -738 M | -738 M | -738 M | -653 M | -651 M | -651 M | -651 M | -267 M | -267 M | -267 M | -267 M | -206 M | -206 M | -206 M | -206 M | -167 M | -167 M | -167 M | -167 M | - | - | - | - | - | - | - | - | - |
Total Assets |
94.6 M | 277 M | 132 M | 97.7 M | 103 M | 117 M | 132 M | 140 M | 160 M | 150 M | 144 M | 159 M | 177 M | 191 M | 195 M | 204 M | - | 237 M | 204 M | 166 M | 135 M | 146 M | 137 M | 137 M | 137 M | 137 M | 106 M | 106 M | 106 M | 106 M | 228 M | 228 M | 228 M | 228 M | 237 M | 237 M | 237 M | 237 M | 276 M | 276 M | 276 M | 276 M | 712 M | 712 M | 712 M | 712 M | 118 M | 118 M | 118 M | 118 M | 71.7 M | 71.7 M | 71.7 M | 71.7 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
36.3 M | 23.7 M | 26.3 M | 22.4 M | 37.4 M | 37.1 M | 36.3 M | 31.8 M | 62.8 M | 43.1 M | 26.3 M | 17.5 M | 27.2 M | 40.6 M | 30.8 M | 24 M | 47.3 M | 81.3 M | 109 M | 77.9 M | 31 M | 79.4 M | 52.3 M | 52.3 M | 52.3 M | 52.3 M | 31.8 M | 31.8 M | 31.8 M | 31.8 M | 36.9 M | 36.9 M | 36.9 M | 36.9 M | 54.3 M | 54.3 M | 54.3 M | 54.3 M | 23.4 M | 23.4 M | 23.4 M | 23.4 M | 167 M | 167 M | 167 M | 167 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 68.7 M | 68.7 M | 68.7 M | 68.7 M | 47 M | - | - | - | 9.03 M | - | - | - | 12.4 M |
Book Value |
76.6 M | 260 M | 97.4 M | 77.4 M | 83 M | 79.2 M | 97.4 M | 107 M | 122 M | 115 M | 106 M | 119 M | 135 M | 144 M | 137 M | 146 M | - | 166 M | 169 M | 130 M | 101 M | 114 M | 102 M | 102 M | 102 M | 102 M | 72.7 M | 72.7 M | 72.7 M | 72.7 M | 200 M | 200 M | 200 M | 200 M | 182 M | 182 M | 182 M | 182 M | 203 M | 203 M | 203 M | 203 M | 548 M | 548 M | 548 M | 548 M | 88 M | 88 M | 88 M | 88 M | 59.2 M | 59.2 M | 59.2 M | 59.2 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
97.4 M | 260 M | 106 M | 77.4 M | 83 M | 79.2 M | 97.4 M | 107 M | 122 M | 115 M | 106 M | 119 M | 135 M | 144 M | 137 M | 146 M | 153 M | 166 M | 169 M | 130 M | 101 M | 114 M | 102 M | 102 M | 102 M | 102 M | 72.7 M | 72.7 M | 72.7 M | 72.7 M | 200 M | 200 M | 200 M | 200 M | 182 M | 182 M | 182 M | 182 M | 203 M | 203 M | 203 M | 203 M | 548 M | 548 M | 548 M | 548 M | 88 M | 88 M | 88 M | 88 M | 59.2 M | 59.2 M | 59.2 M | 59.2 M | 40.9 M | - | - | - | 5.23 M | - | - | - | 10.8 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Arbutus Biopharma Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
